These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38821601)

  • 21. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model.
    Miki K; Xu M; An Z; Wang X; Yang M; Al-Refaie W; Sun X; Baranov E; Tan Y; Chishima T; Shimada H; Moossa AR; Hoffman RM
    Cancer Gene Ther; 2000 Feb; 7(2):332-8. PubMed ID: 10770644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis.
    Machover D; Zittoun J; Saffroy R; Broët P; Giraudier S; Magnaldo T; Goldschmidt E; Debuire B; Orrico M; Tan Y; Mishal Z; Chevallier O; Tonetti C; Jouault H; Ulusakarya A; Tanguy ML; Metzger G; Hoffman RM
    Cancer Res; 2002 Aug; 62(16):4685-9. PubMed ID: 12183426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid.
    Machover D; Zittoun J; Broët P; Metzger G; Orrico M; Goldschmidt E; Schilf A; Tonetti C; Tan Y; Delmas-Marsalet B; Luccioni C; Falissard B; Hoffman RM
    Biochem Pharmacol; 2001 Apr; 61(7):867-76. PubMed ID: 11274973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
    Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
    Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyaki M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh AS; Chmielowski B; Nelson SD; Russell TA; Eckardt MA; Dry SM; Li Y; Singh SR; Chawla SP; Eilber FC; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2018 Dec; 506(4):912-917. PubMed ID: 30392912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Methioninase as a DNA Demethylation Agent.
    Hoffman RM; Machover D
    Methods Mol Biol; 2019; 1866():279-284. PubMed ID: 30725424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
    Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
    Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of PD-L1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human Colorectal Cancer Cells.
    Mizuta K; Kang BM; Han Q; Kubota Y; Morinaga S; Sato M; Bouvet M; Tome Y; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2024; 21(4):395-398. PubMed ID: 38944421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergy of Rapamycin and Methioninase on Colorectal Cancer Cells Requires Simultaneous and Not Sequential Administration: Implications for mTOR Inhibition.
    Ardjmand D; Sato M; Han Q; Kubota Y; Mizuta K; Morinaga S; Hoffman RM
    Cancer Diagn Progn; 2024; 4(4):396-401. PubMed ID: 38962555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective Metabolic Targeting of Human Osteosarcoma Cells
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Murakami T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Hoffman RM
    Anticancer Res; 2017 Sep; 37(9):4807-4812. PubMed ID: 28870899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
    Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad selective efficacy of rMETase and PEG-rMETase on cancer cells in vitro.
    Tan Y; Xu M; Hoffman RM
    Anticancer Res; 2010 Mar; 30(3):793-8. PubMed ID: 20392998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methioninase Cell-Cycle Trap Cancer Chemotherapy.
    Hoffman RM; Yano S; Igarashi K
    Methods Mol Biol; 2019; 1866():133-148. PubMed ID: 30725413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.